 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Over the last three days, A.I.dvisor has detected that CBAY's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

CymaBay Therapeutics (CBAY, $32.48) Aroon Indicator entered an Uptrend on March 21, 2024.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in...

Gilead Sciences Announces Completion of Acquisition of CymaBay

CymaBay Therapeutics (CBAY, $32.47) Aroon Indicator entered an Uptrend on March 20, 2024.

CymaBay Therapeutics (CBAY, $32.48) Aroon Indicator entered an Uptrend on March 19, 2024.

CymaBay Therapeutics (CBAY, $32.48) Aroon Indicator entered an Uptrend on March 18, 2024.

Investment analysts at StockNews.com assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY  Get Free Report) in a research note issued to investors on Sunday. The brokerage set a...

CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated at StockNews.com

CymaBay Therapeutics (CBAY, $32.45) Aroon Indicator entered an Uptrend on March 15, 2024.

CymaBay Therapeutics (CBAY, $32.47) Aroon Indicator entered an Uptrend on March 14, 2024.

CymaBay Therapeutics (CBAY, $32.44) Aroon Indicator entered an Uptrend on March 13, 2024.

CymaBay Therapeutics (CBAY, $32.45) Aroon Indicator entered an Uptrend on March 12, 2024.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.  Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Volume (M)	8.36M
52-Wk High	$32.50
52-Wk Low	$7.26

CBAY Cymabay Therapeutics Inc

About

Feed

News

Earnings

Fundamentals